Goldman Sachs Reiterates Conviction Buy on Gilead Sciences (GILD)
Shares of Gilead Sciences opened at 49.90 on Monday. Gilead Sciences has a one year low of $34.45 and a one year high of $56.50. The company has a market cap of $37.834 billion and a P/E ratio of 15.01.
Gilead Sciences last issued its quarterly earnings data on Thursday, April 26th. The company reported $0.91 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.94 by $0.03. Gilead Sciences’s revenue was up 18.5% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $0.96 earnings per share next quarter.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Gilead Sciences in a research note to investors on Monday, April 30th. They now have a $55.00 price target on the stock. Separately, analysts at Citigroup (NYSE: C) raised their price target on shares of Gilead Sciences to $64.00 in a research note to investors on Friday, April 27th. They now have a “buy” rating on the stock. Finally, analysts at Needham & Company raised their price target on shares of Gilead Sciences from $54.00 to $56.00 in a research note to investors on Friday, April 27th. They now have a “buy” rating on the stock.
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.